[PDF][PDF] Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or …
JB Vermorken, J Trigo, R Hitt, P Koralewski… - Journal of clinical …, 2007 - Citeseer
JB Vermorken, J Trigo, R Hitt, P Koralewski, E Diaz-Rubio, F Rolland, R Knecht, N Amellal…
Journal of clinical oncology, 2007•CiteseerPurpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent
and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) who experience
disease progression on platinum therapy.
monoclonal antibody cetuximab administered as a single agent in patients with recurrent
and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) who experience
disease progression on platinum therapy.
Purpose
To evaluate the efficacy and safety of the epidermal growth factor receptor–directed monoclonal antibody cetuximab administered as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) who experience disease progression on platinum therapy.
Citeseer